Several Drugs Have Similar Efficacy for Plaque Psoriasis
WEDNESDAY, Feb. 19, 2020 -- Four drugs have similar Psoriasis Area and Severity Index (PASI) response rates for both short- and long-term treatment of plaque psoriasis, according to a review published online Feb. 5 in JAMA Dermatology. April W.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 19, 2020 Category: Pharmaceuticals Source Type: news

Study Probes Side Effects of Methotrexate, Used for Psoriasis, Rheumatoid Arthritis
Title: Study Probes Side Effects of Methotrexate, Used for Psoriasis, Rheumatoid ArthritisCategory: Health NewsCreated: 2/18/2020 12:00:00 AMLast Editorial Review: 2/19/2020 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - February 19, 2020 Category: Rheumatology Source Type: news

Evaluating risk of cancer in patients with psoriasis, psoriatic arthritis
(JAMA Network) This observational study was a systematic review and meta-analysis that included 112 studies and examined the association between risk of cancer in patients with psoriasis or psoriatic arthritis, including the risk of specific cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 19, 2020 Category: Cancer & Oncology Source Type: news

Study Probes Side Effects of Methotrexate, Used for Psoriasis, Rheumatoid Arthritis
TUESDAY, Feb. 18, 2020 -- Many Americans battling autoimmune illnesses such as rheumatoid arthritis or psoriasis turn to a long-used drug, methotrexate, for relief. But until now there's been little comprehensive research on side effects tied to... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 18, 2020 Category: General Medicine Source Type: news

SMAC mimetics and RIPK inhibitors as therapeutics for chronic inflammatory diseases
New therapeutic approaches for chronic inflammatory diseases such as inflammatory bowel disease, rheumatoid arthritis, and psoriasis are needed because current treatments are often suboptimal in terms of both efficacy and the risks of serious adverse events. Inhibitor of apoptosis proteins (IAPs) are E3 ubiquitin ligases that inhibit cell death pathways and are themselves inhibited by second mitochondria-derived activator of caspases (SMAC). SMAC mimetics (SMs), small-molecule antagonists of IAPs, are being evaluated as cancer therapies in clinical trials. IAPs are also crucial regulators of inflammatory pathways because t...
Source: Signal Transduction Knowledge Environment - February 18, 2020 Category: Science Authors: Jensen, S., Seidelin, J. B., LaCasse, E. C., Nielsen, O. H. Tags: STKE Reviews Source Type: news

Secukinumab Without the Loading Dose in Chronic Psoriasis Secukinumab Without the Loading Dose in Chronic Psoriasis
Can secukinumab be administered without the initial loading dose in patients with psoriasis without compromising its effectiveness?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 11, 2020 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Crescita Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Studies for its Lead Pipeline Product in Patients with Plaque Psoriasis
Primary Endpoint Achieved with High Statistical Significance LAVAL, QC, Feb. 11, 2020 -- (Healthcare Sales & Marketing Network) – Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) ("Crescita" or the "Company"), a commercial derm... Biopharmaceuticals, Drug Delivery, Dermatology Crescita Therapeutics, MMPE, plaque psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 11, 2020 Category: Pharmaceuticals Source Type: news

Biologics Tied to Greater Reduction in Pediatric Psoriasis
MONDAY, Feb. 10, 2020 -- Biologics seem to be associated with greater reduction in psoriasis severity scores and higher drug survival rates than methotrexate in pediatric patients treated in a real-world setting, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 10, 2020 Category: Pharmaceuticals Source Type: news

Prenatal Tobacco Exposure May Raise Risk for Pediatric Psoriasis
FRIDAY, Feb. 7, 2020 -- Prenatal tobacco exposure is associated with an increased risk for pediatric psoriasis, according to a study published online Jan. 20 in the Journal of the American Academy of Dermatology. Jonathan Groot, M.Sc.P.H., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 7, 2020 Category: Pharmaceuticals Source Type: news

Lab Discovery Offers Promise for Treating Multiple Sclerosis
WEDNESDAY, Feb. 5, 2020 -- A new discovery could lead to better treatments for multiple sclerosis (MS) and other autoimmune diseases, such as psoriasis and rheumatoid arthritis, researchers report. MS occurs when immune cells get into the central... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 5, 2020 Category: General Medicine Source Type: news

Eli Lilly profit tops estimates on diabetes drug strength
Eli Lilly and Co reported a higher-than-expected quarterly profit on Thursday, helped by strong demand for its diabetes drug, Trulicity, and psoriasis treatment, Taltz. (Source: Reuters: Health)
Source: Reuters: Health - January 30, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Familial Psoriasis May Not Be Tied to Obesity
WEDNESDAY, Jan. 29, 2020 -- Obesity does not necessarily induce or contribute to familial psoriasis, according to a study published online Jan. 17 in the Journal of Dermatology. Bolortuya Bayaraa, M.D., from Fukuoka University in Japan, and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 29, 2020 Category: Pharmaceuticals Source Type: news

Tildrakizumab for Moderate-to-Severe Plaque Psoriasis Tildrakizumab for Moderate-to-Severe Plaque Psoriasis
Review the latest clinical studies on tildrakizumab, a promising new monoclonal antibody targeting IL-23p19, for patients with moderate-to-severe chronic plaque psoriasis.Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 23, 2020 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Depression and suicidality in psoriasis and clinical studies of brodalumab: a narrative review - Koo J, Ho RS, Thibodeaux Q.
Patients with psoriasis have high rates of depression and may be at increased risk for suicidal ideation and behavior (SIB). Attempted and completed suicides during clinical trials and other studies of psoriasis therapies, including brodalumab, highlight t... (Source: SafetyLit)
Source: SafetyLit - January 17, 2020 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Medical News Today: Itchy rash: 8 types
Many different factors and conditions can lead to an itchy rash, including eczema, skin allergies, and psoriasis. Read about some of them here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 14, 2020 Category: Consumer Health News Tags: Dermatology Source Type: news

Psoriasis treatment: Including this food in your diet may help relieve the skin condition
PSORIASIS is a condition that affects the skin, causing red, flaky and crusty patches of skin and can prove very irritating. But what can you do to treat it? Including a certain food in your diet could help. (Source: Daily Express - Health)
Source: Daily Express - Health - January 9, 2020 Category: Consumer Health News Source Type: news

Drug developer dips on failed psoriasis trial
Shares of drug developer Durect Corp. shed nearly a third of their value Thursday after the Cupertino company said its headline drug failed a mid-stage clinical trial aimed at people with itchy, scaly psoriasis. Durect's drug, called DUR-928, has been closely watched not only because of of the psoriasis study but because it also is being tested as a treatment for alcoholic hepatitis and nonalcoholic steatohepatitis, or NASH — a fatty liver disease that is one of the hottest potential commercial… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 2, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Drug developer dips on failed psoriasis trial
Shares of drug developer Durect Corp. shed nearly a third of their value Thursday after the Cupertino company said its headline drug failed a mid-stage clinical trial aimed at people with itchy, scaly psoriasis. Durect's drug, called DUR-928, has been closely watched not only because of of the psoriasis study but because it also is being tested as a treatment for alcoholic hepatitis and nonalcoholic steatohepatitis, or NASH — a fatty liver disease that is one of the hottest potential commercial… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 2, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Inflammation Linked to Thyroid Dysfunction in Psoriasis Patients
MONDAY, Dec. 30, 2019 -- While the rate of thyroid dysfunction among patients with psoriasis generally is not higher than expected, psoriasis in patients with thyroid dysfunction is more clinically severe and serum levels of C-reactive protein (CRP)... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 30, 2019 Category: Pharmaceuticals Source Type: news

Adalimumab in Pediatric Patients With Severe Plaque Psoriasis Adalimumab in Pediatric Patients With Severe Plaque Psoriasis
This analysis reports results from the first RCT comparing the efficacy and safety of the biologic adalimumab with methotrexate for severe plaque psoriasis in children.The British Journal of Dermatology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - December 27, 2019 Category: Allergy & Immunology Tags: Dermatology Journal Article Source Type: news

Living Systematic Review: Pharmacological treatments for psoriasis, network meta analysis
The objectives of our review were to compare the efficacy and safety of conventional systemic agents for patients with moderate to severe psoriasis and to provide a ranking of these treatments according to their efficacy and safety by the mean of a network meta-analysis.Our review included 140 studies (31 new studies for the update) and 51,749 participants.  Is it the first iteration of this Living Systematic Review (LSR) or an update?This review was published for the first time in December 2017. This version evolves this review into a LSR. This current version is both an update and first occurrence of the LSR.How oft...
Source: Cochrane News and Events - December 17, 2019 Category: Information Technology Authors: Katie Abbotts Source Type: news

Biocon extends licensing pact with Equillium for itolizumab
Itolizumab, a first-in-class humanized anti-CD6 monoclonal antibody, is developed by Biocon and launched in 2013 in India under the brand name ALZUMAb to treat moderate to severe plaque psoriasis, a skin disease. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 12, 2019 Category: Pharmaceuticals Source Type: news

Type 2 Diabetes More Common in Patients With Psoriasis
WEDNESDAY, Dec. 11, 2019 -- Rates of type 2 diabetes may be higher among patients with psoriasis, according to a study published online Dec. 3 in the Journal of the European Academy of Dermatology and Venereology. Wiebke Sondermann, Dr. Med., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 11, 2019 Category: Pharmaceuticals Source Type: news

Insights into Psoriasis Suggest a New Treatment Target
Investigators from Brigham and Women ’s Hospital and the Harvard Stem Cell Institute have uncovered a novel pathway that may explain why skin thickens in psoriasis and suggests new strategies for developing therapies for the condition. (Source: BWH News)
Source: BWH News - December 11, 2019 Category: Hospital Management Source Type: news

Weight Loss and Severity of Psoriasis or Psoriatic Arthritis Weight Loss and Severity of Psoriasis or Psoriatic Arthritis
This review examined the impact of weight loss on pre-existing psoriasis or psoriatic arthritis. Might losing weight prevent the onset of psoriasis in obese individuals?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 10, 2019 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Study examines sex differences in potential link between psoriasis and metabolic disorders
(Wiley) An analysis published in the Journal of the European Academy of Dermatology and Venereology revealed considerable sex differences when considering links between psoriasis and metabolic disorders. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 4, 2019 Category: International Medicine & Public Health Source Type: news

Palmoplantar Pustulosis Confirmed as Orphan Disease
TUESDAY, Dec. 3, 2019 -- Co-occurring psoriasis is common among patients with palmoplantar pustulosis (PPP), according to a study published in the November issue of the British Journal of Dermatology. Yuki M.F. Andersen, from the University of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 3, 2019 Category: Pharmaceuticals Source Type: news

Natural relief from psoriasis, thanks to TCM
(Natural News) Psoriasis is a common skin disease that affects more than 200 million people worldwide. Although it is non-contagious and has a tendency to come and go, psoriasis is chronic, painful, and most of all, disfiguring. Hence, the search for a definitive cure for this disease, as well as ways of improving the quality of life of psoriasis patients, is... (Source: NaturalNews.com)
Source: NaturalNews.com - December 3, 2019 Category: Consumer Health News Source Type: news

FDA Approves RediTrex (methotrexate) for Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Psoriasis
NASHVILLE, Tenn., Dec. 2, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for RediTrex, its new... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 2, 2019 Category: Drugs & Pharmacology Source Type: news

FDA approves Pfizer's biosimilar, ABRILADA ™ (adalimumab-afzb) for multiple inflammatory conditions
Pfizer Inc. (NYSE: PFE) announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),(1) for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.(2) (Source: World Pharma News)
Source: World Pharma News - December 2, 2019 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Podcast: Lifestyle changes for treating psoriasis
We examined the research evidence that was available up to July 2018, and identified 10 relevant randomised trials, with a total of approximately 1,200 participants. The quality of evidence was moderate to low, with study limitations including participants knowing which treatment they were receiving and a large number of withdrawals from the trials.However, we were able to draw some conclusions. We found that among obese patients with psoriasis, dietary intervention with a low-calorie diet may reduce the severity of psoriasis, and probably improves their quality of life and reduces their body mass index, or BMI. Also, amon...
Source: Cochrane News and Events - November 28, 2019 Category: Information Technology Authors: Lydia Parsonson Source Type: news

Psoriasis sufferer cures skin condition after ditching dairy and red meat
Georgia Robinson, 25, from Birmingham, was left covered head-to-toe in a red, flaky rash. Strangers hurled abuse at her in the street and called her a burns victim. She claims she cured the condition. (Source: the Mail online | Health)
Source: the Mail online | Health - November 26, 2019 Category: Consumer Health News Source Type: news

Amgen completes acquisition of Otezla ® (apremilast)
Amgen (NASDAQ:AMGN) today announced the successful completion of its acquisition of worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for moderate-to-severe plaque psoriasis and psoriatic arthritis. Otezla was acquired from Celgene Corporation (NASDAQ:CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company (NYSE:BMY), which was completed on Nov. 20. (Source: World Pharma News)
Source: World Pharma News - November 21, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Palmoplantar Psoriasis: Does a New Drug Offer Some Relief? Palmoplantar Psoriasis: Does a New Drug Offer Some Relief?
Palmoplantar psoriasis is miserable to live with and equally miserable to treat. Will guselkumab prove to be a better option?Medscape Dermatology (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - November 21, 2019 Category: Dermatology Tags: Dermatology Viewpoint Source Type: news

MC2 Therapeutics Announces FDA Acceptance of its New Drug Application for Wynzora ™ Cream for Treatment of Plaque Psoriasis
Copenhagen, November 20th, 2019 – MC2 Therapeutics, an emerging pharmaceutical company focused on novel PAD™ Technology-based topical therapies for chronic inflammatory conditions, today announced that the U.S. Food and Drug... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - November 20, 2019 Category: Drugs & Pharmacology Source Type: news

ACR: Age at Psoriasis Onset Sets Course for Psoriatic Arthritis
TUESDAY, Nov. 12, 2019 -- For patients with psoriatic arthritis (PsA), the age of psoriasis onset determines whether arthritis or psoriasis starts first, according to a study presented at the annual meeting of the American College of Rheumatology,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 12, 2019 Category: Pharmaceuticals Source Type: news

Woman whose skin was covered with red raw patches makes remarkable transformation
Briseis Lunn, 29, from Nottingham, suffers from psoriasis, which causes the flaky patches to break out across her face, body and even under her eyelids. (Source: the Mail online | Health)
Source: the Mail online | Health - November 6, 2019 Category: Consumer Health News Source Type: news

Medical News Today: Can you prevent psoriatic arthritis?
It is impossible to know who will develop psoriatic arthritis, though it usually affects people who already have psoriasis. Learn about whether people can prevent psoriatic arthritis here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 4, 2019 Category: Consumer Health News Tags: Psoriatic Arthritis Source Type: news

New data show how ICER ’s value framework could prevent or delay access to treatments for Medicaid patients across the country
Anew analysis from Xcenda applied the Institute for Clinical and Economic Review ’s (ICER) value assessments to state Medicaid programs inCalifornia,Massachusetts,Maryland,NevadaandNew York. The study found these one-size-fits-all value assessments could prevent or delay access to prescriptions to treat serious, complex conditions like multiple sclerosis (MS), rheumatoid arthritis (RA), non-small cell lung cancer (NSCLC) and psoriasis. (Source: The Catalyst)
Source: The Catalyst - November 4, 2019 Category: Pharmaceuticals Authors: Katie Koziara Tags: Access Medicaid Value-Driven Health Care The Value Collaborative Source Type: news

Substantial regional differences in access to care for psoriasis in US
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2019 Category: Drugs & Pharmacology Source Type: news

Medical News Today: Some keto diets may exacerbate skin inflammation
A study in mouse models with psoriasis-like skin inflammation suggests that ketogenic diets with a very high fat content may exacerbate skin problems. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 18, 2019 Category: Consumer Health News Tags: Nutrition / Diet Source Type: news

Risk for Cancer Incidence, Mortality Increased With Psoriasis
WEDNESDAY, Oct. 16, 2019 -- Patients with psoriasis have an increased risk for developing or dying from cancer, according to a review published online Oct. 16 in JAMA Dermatology. Alex M. Trafford, from the University of Manchester in the United... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 16, 2019 Category: Pharmaceuticals Source Type: news

Psoriasis Tied to Increased Cancer Risk
Among people with psoriasis, the risk of skin, esophageal, liver and pancreatic cancer was particularly high. (Source: NYT Health)
Source: NYT Health - October 16, 2019 Category: Consumer Health News Authors: Nicholas Bakalar Tags: Pancreatic Cancer Psoriasis Liver Skin Source Type: news

Lilly Presents Positive Results for Taltz & #194; & #174; (ixekizumab) in Pediatric ...
Taltz is the first and only IL-17A inhibitor with published clinical trial results in pediatric patients with moderate to severe plaque psoriasis Indianapolis, Oct. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz met co-primary endpoints as well as all major secondary endpoints in a Phase 3 study in pediatric patients with moderate to severe plaque psoriasis, demonstrating that 89 percent of patients treated with Taltz achieved a significant...This story is related to the following:Pharmaceuticals (Source: Industrial Newsroom - Health, Medical and Dental Supplies)
Source: Industrial Newsroom - Health, Medical and Dental Supplies - October 15, 2019 Category: Medical Devices Source Type: news

Novel Treatment for Plaque Psoriasis Shows Long-term Benefit Novel Treatment for Plaque Psoriasis Shows Long-term Benefit
The reSURFACE 1 and 2 studies show 4-year benefits with the monoclonal antibody for patients with moderate to severe plaque psoriasis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 14, 2019 Category: Consumer Health News Tags: Dermatology News Source Type: news

Long-term Benefit in Psoriasis With Monoclonal Antibody Long-term Benefit in Psoriasis With Monoclonal Antibody
The reSURFACE 1 and 2 studies show 4-year benefits with tildrakizumab for patients with moderate to severe plaque psoriasis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 14, 2019 Category: Consumer Health News Tags: Dermatology News Source Type: news

Healthy diet improved depression symptoms in young adults
Eating less processed food and more fruit, vegetables, fish and olive oil improved depression symptoms Related items fromOnMedica Psoriasis linked to raised risk of many mental health problems GPs need more time to treat complex needs Report reveals toll of living with rare diseases Mental health services face double whammy Should we recognise obesity as a disease? (Source: OnMedica Latest News)
Source: OnMedica Latest News - October 11, 2019 Category: UK Health Source Type: news

Used for thousands of years in TCM, Psoralea corylifolia treats a variety of diseases from heart disease to cancer
(Natural News) Psoralea corylifolia or babchi is a medicinal herb that is popular among traditional Chinese medicine and Ayurveda practitioners. It is used to treat various skin diseases, including rashes, psoriasis, leprosy, and leucoderma – a condition that causes the appearance of white patches due to loss of melanin. However, several studies have reported that P. corylifolia has other clinical applications, and... (Source: NaturalNews.com)
Source: NaturalNews.com - October 8, 2019 Category: Consumer Health News Source Type: news

New Head-to-Head Data Show Taltz(R) (ixekizumab) Superiority versus TREMFYA(R) (guselkumab) in People with Moderate to Severe Plaque Psoriasis
Taltz met the primary endpoint of the IXORA-R study, with 41.3 percent of patients taking Taltz achieving complete skin clearance as measured by PASI 100 at Week 12 versus 24.9 percent of patients taking TREMFYA Taltz also met all major secondary endpoi... Biopharmaceuticals, Dermatology Eli Lilly, Taltz, ixekizumab, plaque psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 3, 2019 Category: Pharmaceuticals Source Type: news

The Singing Detective had it, and so does Kim Kardashian, STEFANIE WILLIAMS on tackling psoriasis
STEFANIE WILLIAMS: As of last week, psoriasis found a new face - and body - in reality TV star Kim Kardashian-West. Today, more than a million Britons are affected to some extent. (Source: the Mail online | Health)
Source: the Mail online | Health - September 28, 2019 Category: Consumer Health News Source Type: news